mdlinx mdlinx
Latest (38) Full Text Articles (3243) Focus on Vascular Disorders-Stroke Article Summary

Ziprasidone and the Corrected QT Interval: A Comprehensive Summary of Clinical Data
CNS Drugs,  Clinical Article

Camm AJ et al. – The analyses provide the first comprehensive summary of QT interval (QTc) changes associated with ziprasidone based on Pfizer–sponsored phase II–IV randomized controlled trials (RCTs), safety reports and post–marketing surveillance. The results of the analyses of pooled data from phase II–IV RCTs in adults demonstrate a modest mean increase in QTc, infrequent QTc prolongation ≥60 ms and rare observation of QTc ≥480 ms. These data are consistent with results from ziprasidone clinical pharmacology studies, safety reports and post–marketing surveillance. Taken together, they provide the most comprehensive evidence published to date that ziprasidone appears to be safe when used as indicated in patients with schizophrenia or bipolar disorder.

Methods
  • The following analyses of data were conducted to obtain a comprehensive summary of QTc data on ziprasidone:
    • Post hoc analyses (using primarily descriptive statistics) of pooled QTc data (Fridericia correction) from more than 40 phase II-IV adult ziprasidone RCTs organized according to the following subgroups: all monotherapy studies in schizophrenia and bipolar disorder, all intramuscular (IM) studies, adjunctive studies in bipolar disorder and fixed-dose oral studies
    • Post hoc analyses from 36 phase II-IV adult ziprasidone RCTs exploring the relationship between QTc change from baseline and baseline QTc in adults
    • Post hoc analyses from phase II-IV adult ziprasidone RCTs modelling QTc change as a function of ziprasidone concentration in both adult (17 studies) and paediatric (5 studies) subjects
    • Cardiac adverse event (AE) reports from all phase II-IV adult ziprasidone RCTs in schizophrenia
    • A large simple trial entitled Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC) in 18,154 subjects with schizophrenia (the only previously reported results included here); and
    • Cardiac-related AEs presented in a ziprasidone post-marketing surveillance report created in 2007.

Results
  • A total of 4306 adults received ziprasidone in placebo- and active-comparator phase II–IV RCTs and had evaluable QTc data.
  • One subject reached a QTc ≥480 ms; 33 (0.8%) had a QTc ≥450 ms.
  • QTc prolongation ≥30 ms was observed in 389 subjects (9.0%); ≥60 ms in 30 (0.7%); and ≥75 ms in 12 (0.3%).
  • In the placebo-controlled studies, mean change in QTc from baseline to end of study was 3.6 (± 20.8) ms in the ziprasidone group; the corresponding QTc change in the pooled placebo group was -0.3 (± 20.6) ms.
  • Data from IM studies, and bipolar studies in which ziprasidone was used adjunctively with lithium, valproate or lamotrigine, demonstrated similar QTc effects.
  • A scatter-plot of QTc prolongation against baseline QTc showed QTc prolongation ≥60 ms exclusively in adult subjects with a baseline QTc ≤400 ms.
  • The final concentration-response analysis model, comprising 2966 data points from 1040 subjects, estimates an increase in QTc of 6 ms for each 100 ng/mL increase in ziprasidone concentration.
  • The large simple trial (ZODIAC) failed to show that ziprasidone is associated with an elevated risk of non-suicidal mortality relative to olanzapine in real-world use.
  • Post-marketing data over a 5-year period did not show a signal of increased cardiac AEs.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Cardiology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Cardiology Articles

Last month's top read Top Articles of 2013

1 Vitamin D deficiency and coronary artery disease: A review of the evidence American Heart Journal, March 5, 2014    Review Article

2 Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: A meta-analysis of >35,000 patients International Journal of Cardiology, March 17, 2014    Clinical Article

3 Atenolol versus non-atenolol beta-blockers for the treatment of hypertension: a meta analysis Canadian Journal of Cardiology, February 10, 2014    Evidence Based Medicine    Review Article    Clinical Article

4 Beta blockers in hypertension: studies and meta-analyses over the years Canadian Journal of Cardiology, March 21, 2014    Evidence Based Medicine    Review Article    Clinical Article

5 Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: Effects of Statin (HMGCoA-Reductase Inhibitor) Therapy Clinical Drug Investigation, March 3, 2014    Clinical Article

6 Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial International Journal of Cardiology, February 18, 2014    Clinical Article

7 Comparative coronary risks of apixaban, rivaroxaban and dabigatran: A meta-analysis and adjusted indirect comparison British Journal of Clinical Pharmacology, March 13, 2014    Evidence Based Medicine

8 Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation EP Europace, March 4, 2014    Clinical Article

9 Aspirin use in heart failure Circulation: Heart Failure, March 20, 2014    Clinical Article

10 Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: A randomized, placebo-controlled trial Full Text Nutrition Journal, November 15, 2013    Free full text    Clinical Article

11 Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting The American Journal of Cardiology, January 30, 2014    Evidence Based Medicine    Review Article    Clinical Article

12 What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice European Journal of Preventive Cardiology, March 18, 2014    Evidence Based Medicine    Review Article    Clinical Article

13 An unusual cause of dyspnoea in a young man European Heart Journal, March 3, 2014

14 Update on the efficacy of statin treatment in Acute Coronary Syndromes European Journal of Clinical Investigation, March 14, 2014    Review Article    Clinical Article

15 Application of new cholesterol guidelines to a population-based sample New England Journal of Medicine, March 24, 2014    Evidence Based Medicine    Clinical Guideline    Clinical Article

16 Long-term coffee consumption and risk of cardiovascular disease Circulation, February 11, 2014    Evidence Based Medicine    Review Article    Clinical Article

17 Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial European Heart Journal, February 28, 2014    Clinical Article

18 High diet quality is associated with a lower risk of cardiovascular disease and all-cause mortality in older men The Journal of Nutrition, March 3, 2014    Clinical Article

19 Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia Cardiovascular Therapeutics, March 26, 2014    Clinical Article

20 Dietary patterns, Mediterranean diet, and cardiovascular disease Current Opinion in Lipidology, March 7, 2014    Review Article

Indexed Journals in Cardiology: American Heart Journal, American Journal of Cardiology, Circulationn, Heartmore

Other Topics in Cardiology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close